MOMariko Ogura

Mariko Ogura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariko Ogura has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer

    by A. Ooki, K. Shimozaki, S. Fukuoka, S. Udagawa, K. Yoshino, K. Yoshikawa, T. Wakatsuki, M. Ogura, E. Shinozaki, K. Chin, et al.

  • Open Access

    High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer

    by Koichiro Yoshino, Hiroki Osumi, Akira Ooki, Shohei Udagawa, Mikako Tamba, Shota Fukuoka, Takeru Wakatsuki, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, et al.

    Background: Oxaliplatin (OXA), a key cytotoxic agent used in the treatment of gastrointestinal cancers, is frequently discontinued due to hypersensitivity reactions (HSRs). We developed a protocol to mitigate HSRs and assessed its clinical efficacy. Methods: We retrospectively analyzed HSRs in patients with metastatic colorectal cancer (mCRC) who were treated with OXA-containing regimens between 2005 and 2019. We evaluated the clinical utility of our HSR prevention protocol in patients who experienced grade 1–3 HSRs following OXA-based chemotherapy. The protocol involved increasing dexamethasone to 16.5 mg/body and extending the OXA infusion time from 2 to 4 h. Results: Among 205 patients, 105 (51.2%) experienced grade 1, 95 (46.3%) grade 2, and 5 (2.4%) grade 3 HSRs. Most patients (87.8%) received either the FOLFOX4 or modified FOLFOX6 regimen. Patients underwent a median of 11 OXA cycles before their initial HSR. OXA was successfully reintroduced in 108 patients (52.7%) using the HSR prevention protocol. The median OXA-free interval was 23 days and the median progression-free survival after reintroduction was 6.4 months (95% confidence interval [CI]: 4.6–8.2). Reasons for discontinuation included a second HSR in 97 patients (47.3%), disease progression in 74 (36.1%), and chemotherapy-induced peripheral neuropathy (CIPN) in 15 (7.3%). Forty-six patients (22.4%) experienced an HSR during the initial prevention protocol. Only six patients (2.9%) experienced grade 3 HSRs and no grade 4 or 5 events were observed. Conclusion: High-dose dexamethasone and prolonged infusion time may enable OXA reintroduction, providing an alternative to permanent discontinuation in mCRC patients with prior HSRs. Registry number: 2024-GB-073 (retrospectively registered).

  • Open Access

    Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer

    by Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka, Shuichi Hironaka, Keiko Minashi, Shigenori Kadowaki, Hidekazu Hirano, Hirokazu Shoji, Toshifumi Yamaguchi, Keisho Chin, et al.

    Background While oncogene co-amplification is frequently observed, its clinical significance remains unclear, particularly with regard to its association with copy number. Objective The aim of this study was to elucidate the molecular traits of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, focusing on copy numbers of ERBB2 and other oncogenes, and to investigate their association with treatment efficacy. Methods This is a collaborative study associated with the HIGHSOX trial investigating the efficacy of trastuzumab combined with S-1 and oxaliplatin in HER2-positive gastric cancer, and next-generation sequencing was performed. Tumors in which ERBB2 was the highest copy number among co-amplified oncogenes were defined as “ERBB2 dominant”. The others were defined as “non-ERBB2 dominant”. Results A total of 32 patients were enrolled, and the median progression-free survival and overall survival were 11.8 and 28.8 months, respectively. ERBB2 amplification was present in 84.4%, with the majority (88%) exhibiting either co-amplification of ERBB2 with other oncogenes (75%) or amplification of other oncogenes alone (13%), including KRAS, MET, FGFR2, and CCNE1. A potential inverse relationship in copy number between ERBB2 and other oncogenes (ρ = − 0.345, p = 0.058) was observed. The ERBB2 copy number was significantly higher than that of other oncogenes in ERBB2-dominant tumors, whereas the opposite pattern was observed in non-ERBB2-dominant tumors (both p < 0.001). Non-ERBB2-dominant tumors showed significantly shorter progression-free survival (median progression-free survival: 6.9 vs 17.0 months, hazard ratio, 6.40, p = 0.001), overall survival (median overall survival 14.8 vs 35.5 months, hazard ratio, 2.72, p = 0.016), and a numerically lower response rate (63.6% vs 90.0%, p = 0.151). Conclusions Copy number-based oncogene dominance may suggest tumor dependence and response to HER2-targeted therapy, highlighting a potential novel biomarker in HER2-positive gastric cancer.


  • Open Access

    BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer

    by T. Wakatsuki, T. Mashima, N. Miyazaki, H. Osumi, S. Fukuoka, A. Ooki, K. Shimozaki, M. Ogura, K. Yoshino, S. Udagawa, et al.

  • Open Access

    Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy

    by A. Ooki, K. Nakano, K. Shimozaki, M. Takamatsu, S. Fukuoka, S. Sakata, H. Osumi, K. Yoshikawa, E. Toyokawa, K. Yoshino, et al.

  • Open Access

    Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

    by Kazuo Kobayashi, Takeru Wakatsuki, Erika Sugiyama, Eiji. Shinozaki, Masataka Tajima, Mariko Ogura, Keisho Chin, Akira Ooki, Hiroki Osumi, Shota Fukuoka, et al.

    The pharmacokinetics of regorafenib and its active metabolites, M2 and M5, vary widely among individual patients. However, the relationship between these plasma concentrations and therapeutic efficacy remains unclear. Patients with metastatic colorectal cancer (mCRC) receiving regorafenib as third‐line or later treatment were enrolled. The initial dose was 120 mg daily for 1 week, then adjusted based on tolerability in a 21‐day on, 7‐day off cycle. Blood samples were collected on Cycle 1 Day 7, and C trough levels of total regorafenib, M2, and M5 were measured using liquid chromatography–tandem mass spectrometry. Thirty‐three patients were enrolled, with a median progression‐free survival (PFS) of 70 days. The median C trough level of regorafenib, M2, and M5 was 2146.9 ng/mL (range: 369.0–5445.9), 1587.2 ng/mL (range: 43.6–6762.7), and 582.9 ng/mL (range: 39.9–352.6), respectively. There was an inverse correlation between PFS and the C trough level of regorafenib ( r = −0.394, p = 0.023). Patients with regorafenib levels ≥ 2848.4 ng/mL had significantly shorter PFS (median 35 vs. 95 days, HR 3.23, 95% CI 1.45–7.25, p = 0.002). In Cycle 1, more frequent serious adverse events (30.0% vs. 4.3%, p = 0.073) and an increased neutrophil‐to‐lymphocyte ratio (median: 3.9 (3.0–5.2) vs. 3.1 (1.1–14.5), p = 0.031) were observed in the higher group. Furthermore, the rate of treatment resumption after interruption during Cycle 1 was significantly lower in the higher group (16.7% vs. 88.9%, p = 0.003). A rapid increase in blood concentrations of regorafenib early after administration resulted in severe toxicity and systemic inflammation, which may have subsequently contributed to shorter PFS.


  • Open Access

    Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor

    by K. Yoshino, M. Tamba, H. Osumi, S. Fukuoka, M. Ogura, S. Udagawa, K. Shimozaki, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, et al.


  • Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

    by Koshiro Fukuda, Hiroki Osumi, Akira Ooki, Daisaku Kamiimabeppu, Shohei Udagawa, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Keisho Chin, Mitsuhiro Fujishiro, et al.

    Background The effect of vascular endothelial growth factor (VEGF) inhibitor pretreatment on clinical outcomes of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC) remains unclear. We aimed to investigate this effect. Methods Patients with mCRC treated with FTD/TPI plus BEV were retrospectively enrolled. Disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared. In total, 73, 50, and 33 patients were treated with fluorouracil+levofolinate calcium+irinotecan (FOLFIRI) plus BEV, ramucirumab, and aflibercept, respectively. Results The DCR and median PFS/OS did not significantly differ among the groups (DCR: 54.8% vs. 56.0% vs. 42.4%, P = 0.43; PFS: 3.9 vs. 4.6 vs. 3.7 months, P = 0.45; OS: 12.0 vs. 9.5 vs. 11.9 months, P = 0.28). The most common grade 3–4 AE was neutropenia. The incidence of grade 3–4 AEs did not significantly differ among the groups. The frequency of grade ≥2 proteinuria during FTD/TPI plus BEV treatment was significantly higher in patients with grade ≥2 proteinuria before FOLFIRI plus VEGF inhibitor use than in those without proteinuria. Multivariate analysis revealed poor performance status (ECOG PS) and liver metastasis as independent predictors of short PFS/OS (ECOG PS, PFS: P = 0.021, OS: P < 0.001; liver metastasis, PFS: P = 0.03, OS: P < 0.001) and grade 3–4 neutropenia in a month as a predictor of long PFS/OS (PFS: P = 0.047, OS: P = 0.03). Conclusion Different pretreatment VEGF inhibitors did not affect the efficacy and safety of FTD/TPI plus BEV.


  • Open Access

    Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

    by Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, et al.

    Purpose: To investigate circulating tumor DNA (ctDNA) RAS mutant (MT) incidence before salvage-line treatment and the clinicopathological features and molecular biological factors associated with the efficacy of anti-epithelial growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for tissue RAS/BRAF wild type (WT) metastatic colorectal cancer (mCRC). Methods: This multi-institutional retrospective observational study included 74 patients with mCRC with tissue RAS/BRAF WT refractory to first-line chemotherapy containing anti-EGFR mAb. ctDNA RAS status was assessed using the OncoBEAM™ RAS CRC Kit. We explored the clinicopathological features associated with ctDNA RAS status and the factors related to anti-EGFR mAb rechallenge efficacy in multivariate Cox proportional hazard regression. Results: The incidence of RAS MT in ctDNA was 40.5% (30/74), which was associated with primary tumor resection (P = 0.016), liver metastasis (P < 0.001), and high tumor marker levels (P < 0.001). Among the 39 patients treated with anti-EGFR mAb rechallenge, those with ctDNA RAS WT showed significantly longer progression-free survival (PFS) than those with ctDNA RAS MT (median 4.1 vs. 2.7 months, hazard ratio [HR] = 0.39, P = 0.045). Patients who responded to first-line anti-EGFR mAb showed significantly longer PFS (HR = 0.21, P = 0.0026) and overall survival (OS) (HR = 0.23, P = 0.026) than those with stable disease. Conclusions: The incidence of ctDNA RAS MT mCRC was 40.5%, which was associated with liver metastases and high tumor volumes. Anti-EGFR mAb rechallenge may be effective for patients with mCRC who responded to first-line chemotherapy containing anti-EGFR mAb. No patients with RAS MT in ctDNA responded to anti-EGFR mAb rechallenge.


  • Open Access

    Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis

    by K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, et al.